185 related articles for article (PubMed ID: 19950571)
1. [Meta-analysis of terlipressin in treatment of hepatorenal syndrome: an update].
Zhang ZF; Yang N; Zhao G; Liu LN; Wang YD; Duan ZJ
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(28):1970-4. PubMed ID: 19950571
[TBL] [Abstract][Full Text] [Related]
2. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
Fabrizi F; Dixit V; Messa P; Martin P
Int J Artif Organs; 2009 Mar; 32(3):133-40. PubMed ID: 19440988
[TBL] [Abstract][Full Text] [Related]
3. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis.
Nassar Junior AP; Farias AQ; D' Albuquerque LA; Carrilho FJ; Malbouisson LM
PLoS One; 2014; 9(9):e107466. PubMed ID: 25203311
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
Facciorusso A; Chandar AK; Murad MH; Prokop LJ; Muscatiello N; Kamath PS; Singh S
Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):94-102. PubMed ID: 28403995
[TBL] [Abstract][Full Text] [Related]
5. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis.
Wang H; Liu A; Bo W; Feng X; Hu Y
Medicine (Baltimore); 2018 Apr; 97(16):e0431. PubMed ID: 29668606
[TBL] [Abstract][Full Text] [Related]
6. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.
Alessandria C; Ottobrelli A; Debernardi-Venon W; Todros L; Cerenzia MT; Martini S; Balzola F; Morgando A; Rizzetto M; Marzano A
J Hepatol; 2007 Oct; 47(4):499-505. PubMed ID: 17560680
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of terlipressin and norepinephrine for treatment of hepatorenal syndrome-acute kidney injury: A systematic review and meta-analysis.
Olson JC; Subramanian RM
PLoS One; 2024; 19(1):e0296690. PubMed ID: 38285703
[TBL] [Abstract][Full Text] [Related]
8. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
Sagi SV; Mittal S; Kasturi KS; Sood GK
J Gastroenterol Hepatol; 2010 May; 25(5):880-5. PubMed ID: 20074149
[TBL] [Abstract][Full Text] [Related]
9. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.
Gifford FJ; Morling JR; Fallowfield JA
Aliment Pharmacol Ther; 2017 Mar; 45(5):593-603. PubMed ID: 28052382
[TBL] [Abstract][Full Text] [Related]
10. Terlipressin in hepatorenal syndrome.
Mazur JE; Cooper TB; Dasta JF
Ann Pharmacother; 2011 Mar; 45(3):380-7. PubMed ID: 21386023
[TBL] [Abstract][Full Text] [Related]
11. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis: terlipressin therapy for the hepatorenal syndrome.
Fabrizi F; Dixit V; Martin P
Aliment Pharmacol Ther; 2006 Sep; 24(6):935-44. PubMed ID: 16948805
[TBL] [Abstract][Full Text] [Related]
13. Terlipressin for hepatorenal syndrome.
Gluud LL; Christensen K; Christensen E; Krag A
Cochrane Database Syst Rev; 2012 Sep; (9):CD005162. PubMed ID: 22972083
[TBL] [Abstract][Full Text] [Related]
14. Terlipressin for hepatorenal syndrome.
Gluud LL; Kjaer MS; Christensen E
Cochrane Database Syst Rev; 2006 Oct; (4):CD005162. PubMed ID: 17054242
[TBL] [Abstract][Full Text] [Related]
15. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
Ghosh S; Choudhary NS; Sharma AK; Singh B; Kumar P; Agarwal R; Sharma N; Bhalla A; Chawla YK; Singh V
Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
[TBL] [Abstract][Full Text] [Related]
16. Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis.
Dobre M; Demirjian S; Sehgal AR; Navaneethan SD
Int Urol Nephrol; 2011 Mar; 43(1):175-84. PubMed ID: 20306131
[TBL] [Abstract][Full Text] [Related]
17. Noradrenaline or terlipressin for hepatorenal syndrome?
Celis P; Rada G
Medwave; 2015 Aug; 15 Suppl 2():e6235. PubMed ID: 26334297
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
Krag A; Borup T; Møller S; Bendtsen F
Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
[TBL] [Abstract][Full Text] [Related]
19. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
Wong F; Pappas SC; Boyer TD; Sanyal AJ; Bajaj JS; Escalante S; Jamil K;
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):266-272.e1. PubMed ID: 27464593
[TBL] [Abstract][Full Text] [Related]
20. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
